The acyclovir legacy: Its contribution to antiviral drug discovery
Author:
- 1 January 1993
- journal article
- new compound
- Published by Wiley in Journal of Medical Virology
- Vol. 41 (S1) , 134-138
Abstract
The discovery of acyclovir marked the beginning of an exciting era in antiviral research. Early studies on the novel mode of action explained the selectivity of the compound and the remarkably narrow spectrum of activity against a subset of the herpesviruses. Throughout the past decade many clinical trials have demonstrated the efficacy and safety of this drug. Furthermore, the development of resistance does not appear to be a significant issue in normal individuals. Acyclovir provided the stimulus for further work in the antiherpes area, and this has led to the recent discovery of an oral prodrug (256U87), which delivers higher levels of acyclovir by the oral route, and to the discovery of 882C87, a highly selective inhibitor of varicella zoster virus. The novel mode of action of acyclovir involves an extremely selective phosphorylation step carried out by the herpesvirus thymidine kinase. It has recently been shown with another nucleoside analogue, ganciclovir, active against human cytomegalovirus (HMCV), that activation can be carried out by other unrelated kinases (in this case the UL97 gene product). Studies of this type may lead to the development of further novel inhibitors.Keywords
This publication has 38 references indexed in Scilit:
- Amino Acid Ester Prodrugs of AcyclovirAntiviral Chemistry and Chemotherapy, 1992
- Acyclovir treatment of varicella in otherwise healthy adolescentsThe Journal of Pediatrics, 1992
- Laboratory studies of herpes simplex virus strains resistant to acyclovirReviews in Medical Virology, 1991
- Analysis of the Protein-Coding Content of the Sequence of Human Cytomegalovirus Strain AD1691990
- Antiherpesvirus activity of 9-(4-hydroxy-3-hydroxy-methylbut-1-yl)guanine (BRL 39123) in cell cultureAntimicrobial Agents and Chemotherapy, 1987
- A human cytomegalovirus mutant resistant to the nucleoside analog 9-([2-hydroxy-1-(hydroxymethyl)ethoxy]methyl)guanine (BW B759U) induces reduced levels of BW B759U triphosphate.Proceedings of the National Academy of Sciences, 1986
- A Double-Blind Study of Oral Acyclovir for Suppression of Recurrences of Genital Herpes Simplex Virus InfectionNew England Journal of Medicine, 1984
- Intravenous acyclovir therapy for varicella in immunocompromised childrenThe Journal of Pediatrics, 1984
- ACYCLOVIR THERAPY FOR ACUTE HERPES ZOSTERThe Lancet, 1982
- Randomised double-blind trial of acyclovir and idoxuridine in dendritic corneal ulceration.British Journal of Ophthalmology, 1980